Trubion Pharmaceuticals (NASDAQ: [[ticker:TRBN]]), a Seattle-based developer of targeted therapies, said today that its experimental TRU-016 treatment showed encouraging results in a small trial of 26 patients with chronic lymphocytic leukemia. The drug reduced the median number of cancer cells circulating in the blood by about two-thirds, researchers said. Researchers have not yet pinpointed a maximum tolerated dose. Detailed data was presented at the American Society of Clinical Oncology meeting in Orlando, FL.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
